[dabigv13]

An interim analysis of the Adaptive COVID-19 Treatment Trial (ACTT) found the drug had a 31% faster time to recovery versus placebo (median 11 days vs 15 days, respectively, P<0.001). It also trended toward a survival benefit (8.0% mortality rate in remdesivir group vs 11.6% in placebo, P=0.059), the NIAID said in a statement.

These would be really positive results if borne out in final analysis. Not a game changer, but at least something to throw at this terrible thing.

What is tricky though is that this med is given by IV, and seems most useful if given early in patients without severe disease. The logstical issues this raises will limit the ultimate effectiveness of this medication in limiting the pandemic.

[dabigv13]

An interim analysis of the Adaptive COVID-19 Treatment Trial (ACTT) found the drug had a 31% faster time to recovery versus placebo (median 11 days vs 15 days, respectively, P<0.001). It also trended toward a survival benefit (8.0% mortality rate in remdesivir group vs 11.6% in placebo, P=0.059), the NIAID said in a statement.

These would be really positive results if borne out in final analysis. Not a game changer, but at least something to throw at this terrible thing.

What is tricky though is that this med is given by IV, and seems most useful if given early in patients without severe disease. The logstical issues this raises will limit the ultimate effectiveness of this medication in limiting the pandemic.